Tenofovir Nephrotoxicity: 2011 Update

被引：217

作者：

Fernandez-Fernandez, Beatriz ^{[1
]}

Montoya-Ferrer, Ana ^{[2
]}

Sanz, Ana B. ^{[3
]}

Sanchez-Nino, Maria D. ^{[3
]}

Izquierdo, Maria C. ^{[1
]}

Poveda, Jonay ^{[1
]}

Sainz-Prestel, Valeria ^{[1
]}

Ortiz-Martin, Natalia ^{[1
]}

Parra-Rodriguez, Alejandro ^{[1
]}

Selgas, Rafael ^{[3
]}

Ruiz-Ortega, Marta ^{[1
]}

Egido, Jesus ^{[1
]}

Ortiz, Alberto ^{[1
,4
]}

机构：

[1] Univ Autonoma Madrid, FRIAT, IRSIN, IIS Fdn Jimenez Diaz,Nefrol, Madrid, Spain

[2] IIS Fdn Jimenez Diaz, Med Interna, Madrid, Spain

[3] Univ Autonoma Madrid, FRIAT, IRSIN, IDiPaz,Nefrol, Madrid, Spain

[4] Fdn Jimenez Diaz, Unidad Dialisis, Madrid 28040, Spain

来源：

AIDS RESEARCH AND TREATMENT | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/354908

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Tenofovir is an acyclic nucleotide analogue reverse-transcriptase inhibitor structurally similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV infection and approved for treatment of hepatitis B virus. Despite initial cell culture and clinical trials results supporting the renal safety of tenofovir, its clinical use is associated with a low, albeit significant, risk of kidney injury. Proximal tubular cell secretion of tenofovir explains the accumulation of the drug in these mitochondriarich cells. Tenofovir nephrotoxicity is characterized by proximal tubular cell dysfunction that may be associated with acute kidney injury or chronic kidney disease. Withdrawal of the drug leads to improvement of analytical parameters that may be partial. Understanding the risk factors for nephrotoxicity and regular monitoring of proximal tubular dysfunction and serumcreatinine in high-risk patients is required tominimize nephrotoxicity. Newer, structurally similarmolecular derivatives that do not accumulate in proximal tubules are under study.

引用

页数：11

共 83 条

[1]

[Anonymous], 2011, GUIDELINES USE ANTIR

[2] Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis [J].

Arribas, Jose R. ;

Pozniak, Anton L. ;

Gallant, Joel E. ;

DeJesus, Edwin ;

Gazzard, Brian ;

Campo, Rafael E. ;

Chen, Shan-Shan ;

McColl, Damian ;

Holmes, Charles B. ;

Enejosa, Jeffrey ;

Toole, John J. ;

Cheng, Andrew K. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) :74-78

[3] Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? [J].

Badiou, Stphanie ;

De Boever, Corinne Merle ;

Terrier, Nathalie ;

Baillat, Vincent ;

Cristol, Jean-Paul ;

Reynes, Jacques .

JOURNAL OF INFECTION, 2006, 52 (05) :335-338

[4] Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].

Barditch-Crovo, P ;

Deeks, SG ;

Collier, A ;

Safrin, S ;

Coakley, DF ;

Miller, M ;

Kearney, BP ;

Coleman, RL ;

Lamy, PD ;

Kahn, JO ;

McGowan, I ;

Lietman, PS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739

[5]

Belongia E A, 2008, NIH Consens State Sci Statements, V25, P1

[6] Changes in the risk of death after HIV seroconversion compared with mortality in the general population [J].

Bhaskaran, Krishnan ;

Hamouda, Osamah ;

Sannes, Mette ;

Boufassa, Faroudy ;

Johnson, Anne M. ;

Lambert, Paul C. ;

Porter, Kholoud .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (01) :51-59

[7] Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors [J].

Birkus, G ;

Hitchcock, MJM ;

Cihlar, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :716-723

[8] Rosiglitazone: a European regulatory perspective [J].

Blind, E. ;

Dunder, K. ;

de Graeff, P. A. ;

Abadie, E. .

DIABETOLOGIA, 2011, 54 (02) :213-218

[9] Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV outpatient study (HOPS) cohort [J].

Buchacz, Kate ;

Young, Benjamin ;

Baker, Rose K. ;

Moorman, Anne ;

Chmiel, Joan S. ;

Wood, Kathy C. ;

Brooks, John T. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :626-628

[10] Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta) [J].

Castillo, AB ;

Tarantal, AF ;

Watnik, MR ;

Martin, RB .

JOURNAL OF ORTHOPAEDIC RESEARCH, 2002, 20 (06) :1185-1189

← 1 2 3 4 5 6 7 8 9 →